Traws Pharma, Inc. (TRAW)

Every figure this model derived for TRAW, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,585,000 PaymentsToAcquireProductiveAssets 2025-12-31
cash 5,016,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 9,023,000 AssetsCurrent 2026-06-30
current liabilities 9,735,000 LiabilitiesCurrent 2026-06-30
equity 1,691,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-06-30
ocf -16,849,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 2,790,000 Revenues 2025-12-31
sbc 1,912,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TRAW on one particular measure came for.

RatioValue
cash operating margin-698.39
current ratio0.95
current ratio reported0.93
deferred revenue growth0.0
dilution pct440.1
fcf margin-696.56
growth cv2.0
operating margin-772.19
owner earnings margin-765.09
revenue growth1134.51
revenue growth per share128.57
rule of 40362.33
sbc pct revenue68.53

What to be careful about

What this model itself distrusts about TRAW's figures. Written by the derivation as it ran, not added afterwards.